Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories Inc. Class A

BTIG analyst Julian Harrison maintained a Buy rating on Jade Biosciences on April 2 and set a price target of $39.00. The company’s shares closed l...

Jade Biosciences (JBIO) Receives a Rating Update from a Top Analyst

Jade Biosciences ( ($JBIO) ) has provided an announcement. On March 31, 2026, Jade Biosciences, Inc.’s board approved the 2026 Employment Inducemen...

Jade Biosciences Adopts 2026 Employment Inducement Stock Plan

Mindbio Therapeutics Corp. ( ($TSE:MBIO) ) has issued an update. MindBio Therapeutics has closed an upsized non-brokered private placement, raising...

MindBio Raises $1.44 Million and Launches Marketing Push for Intoxication Detection Tech

BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an announcement. BioVaxys Technology Corp., a clinical-stage biopharmaceutical company focused on...

BioVaxys Updates on Filing Delays as Executives Face Trading Restrictions

Biome Australia Ltd ( ($AU:BIO) ) has shared an update. Biome Australia Ltd has reported changes to its capital structure following the expiry of a...

Biome Australia Options Lapse Without Exercise, Leaving Share Count Unchanged

BioVersys AG ( ($CH:BIOV) ) has provided an announcement. BioVersys AG has entered an exclusive collaboration and license agreement with U.S. healt...

BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal

BridgeBio Pharma ( ($BBIO) ) has shared an announcement. On March 30, 2026, BridgeBio Pharma announced that it had submitted a New Drug Application...

BridgeBio Files NDA for LGMD2I/R9 Oral Therapy

Fortress Biotech ( ($FBIO) ) has issued an update. On March 30, 2026, Fortress Biotech announced that its majority-owned subsidiary Cyprium Therape...

Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital

Insiders have been trading these 5 stocks: (($ASAN)), (($IBIO)), (($RDW)), (($AFL)) and (($SBSW)). Here is a breakdown of their recent trades and t...

Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA) and Enliven Therapeutics (ELVN). BioAge ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioAge Labs, Inc. (BIOA) and Enliven Therapeutics (ELVN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA). ...

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA)

The latest announcement is out from BioAge Labs, Inc. ( ($BIOA) ). BioAge Labs reported its full-year 2025 results and late-2025 operational milest...

BioAge Highlights BGE-102 Progress and Financial Strength

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00. According to TipRan...

Ibio (IBIO) Receives a Buy from LifeSci Capital

Zenas BioPharma, Inc. ($ZBIO) announced an update on their ongoing clinical study. Zenas BioPharma (ZBIO) is running a phase 3 trial called “A Phas...

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis

The latest announcement is out from Biome Australia Ltd ( ($AU:BIO) ). Biome Australia Ltd has issued 2,513,802 fully paid ordinary shares followin...

Biome Australia Enables Trading of 2.5 Million New Shares After Option Exercises

An announcement from Biome Australia Ltd ( ($AU:BIO) ) is now available. Biome Australia has applied to the ASX for quotation of 2,488,743 new ordi...

Biome Australia Seeks ASX Quotation for New Employee Incentive Shares

An announcement from Biome Australia Ltd ( ($AU:BIO) ) is now available. Biome Australia Ltd has applied to the ASX for quotation of an additional ...

Biome Australia Seeks ASX Quotation for Additional Ordinary Shares

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ibio (IBIO) and Pelthos Therapeutics (PTHS) with bul...

Analysts Offer Insights on Healthcare Companies: Ibio (IBIO) and Pelthos Therapeutics (PTHS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jade Biosciences (JBIO), Hyperfine (HYPR) and Aveann...

Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Hyperfine (HYPR)

Rising tensions in the Middle East and surging oil prices are increasing market volatility, prompting investors to look for defensive assets. Divid...

3 High-Yield Dividend Stocks to Buy in Today’s Volatile Market, According to Analysts, 3/18/2026

An update from Biome Australia Ltd ( ($AU:BIO) ) is now available. Biome Australia Ltd has notified the ASX of a proposed issue of up to 25,059 ful...

Biome Australia Plans Targeted Share Placement on ASX

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Orchestra BioMed Holdings (OBIO – Research Report), ...

Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH)

BioVaxys Technology ( ($TSE:BIOV) ) has provided an update. BioVaxys Technology Corp. reported that it remains under a management cease trade order...

BioVaxys Extends Financial Filing Delay Under Management Cease Trade Order

Bioceres Crop Solutions ( ($BIOX) ) just unveiled an announcement. Bioceres Crop Solutions, a Rosario, Argentina-based agbiotech group listed on Na...

Bioceres Crop Solutions Faces Nasdaq Minimum Bid Price Compliance Deadline

These are the upcoming stock splits for the week of March 16 to March 20, based on TipRanks’ Stock Splits Calendar. For those new to the concept, a...

Upcoming Stock Splits This Week (March 16–20, 2026) – Stay Invested

The latest update is out from Bioceres Crop Solutions ( ($BIOX) ). On March 13, 2026, Bioceres Crop Solutions filed a Form 6-K with the U.S. Securi...

Bioceres Crop Solutions Files December 2025 Interim Financials With SEC

Biome Australia Ltd ( ($AU:BIO) ) just unveiled an announcement. Biome Australia director Blair Vega Norfolk has increased his direct holding in th...

Biome Australia Director Blair Norfolk Increases Direct Shareholding

Chardan Capital analyst Keay Nakae maintained a Buy rating on Orchestra BioMed Holdings today and set a price target of $20.00. According to TipRan...

Orchestra BioMed Holdings (OBIO) Receives a Buy from Chardan Capital

An update from BioVaxys Technology ( ($TSE:BIOV) ) is now available. BioVaxys Technology and Adiverna have entered a research collaboration to deve...

BioVaxys and Adiverna Team Up on AI-Driven mRNA Vaccines for Pets

An update from Harvard Bioscience ( ($HBIO) ) is now available. On March 6, 2026, Harvard Bioscience, Inc. amended and restated the employment agre...

Harvard Bioscience Updates Executive Contracts and Finance Leadership

BridgeBio Pharma received a Buy rating and a $93.03 price target from William Blair analyst today. In addition to William Blair, BridgeBio Pharma a...

BridgeBio Pharma (BBIO) Receives a Buy from William Blair

Biome Australia Ltd ( ($AU:BIO) ) has provided an update. Biome Australia Limited is an Australian-based developer and marketer of evidence-based l...

Biome Australia outlines March 2026 expiry of unlisted options and potential $1.78m capital inflow

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jade Biosciences (JBIO – Research Report) and Dyne T...

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Dyne Therapeutics (DYN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jade Biosciences (JBIO – Research Report) and Dianth...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIO	$278.67	-0.47%	124.39K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIO	$278.67	-0.5%	124.39K
3
4
5
6

BIO

BIO

Dividend Overview

Get Bio-Rad Laboratories Inc. Class A Data in Excel

Get Bio-Rad Laboratories Inc. Class A Data in Excel